TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Brief Summary: The purpose of this study is to gain a better understanding of calcium absorption and metabolism in patients with Chronic Kidney Disease (CKD) using calcium balance and kinetic methods.


Options:
A: Arm Label: K2CG chewing gum (20 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (20mg chitosan) | Arm Label: K2CG chewing gum (60 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (60mg chitosan) | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: K2CG chewing gum (20mg chitosan); Assigned to Arm(s): K2CG chewing gum (20 mg chitosan) | Intervention Type: OTHER; Name: K2CG chewing gum (60mg chitosan); Assigned to Arm(s): K2CG chewing gum (60 mg chitosan)
B: Arm Label: ESRD: FOSTRAP Chewing Gum; Type: ACTIVE_COMPARATOR; Interventions: Other: FOSTRAP Chewing Gum | Arm Label: CKD: FOSTRAP Chewing Gum; Type: ACTIVE_COMPARATOR; Interventions: Other: FOSTRAP Chewing Gum | Arm Label: ESRD Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo chewing gum | Arm Label: CKD Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo chewing gum | Intervention Type: OTHER; Name: FOSTRAP Chewing Gum; Assigned to Arm(s): ESRD: FOSTRAP Chewing Gum | Intervention Type: OTHER; Name: FOSTRAP Chewing Gum; Assigned to Arm(s): ESRD: FOSTRAP Chewing Gum | Intervention Type: OTHER; Name: FOSTRAP Chewing Gum; Assigned to Arm(s): CKD: FOSTRAP Chewing Gum | Intervention Type: OTHER; Name: FOSTRAP Chewing Gum; Assigned to Arm(s): ESRD: FOSTRAP Chewing Gum | Intervention Type: OTHER; Name: Placebo chewing gum; Assigned to Arm(s): CKD Matching Placebo, ESRD Matching Placebo
C: Arm Label: 1 grain (soy) protein diet:; Type: ACTIVE_COMPARATOR; Interventions: Other: grain (soy) protein diet | Arm Label: 2 casein (meat) protein diet; Type: ACTIVE_COMPARATOR; Interventions: Other: casein (meat) protein diet | Intervention Type: OTHER; Name: grain (soy) protein diet; Assigned to Arm(s): 1 grain (soy) protein diet: | Intervention Type: OTHER; Name: casein (meat) protein diet; Assigned to Arm(s): 2 casein (meat) protein diet
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Calcium Carbonate (Phosphate Binder); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: 1500 mg/d elemental calcium as calcium carbonate; Assigned to Arm(s): Calcium Carbonate (Phosphate Binder) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to Less Than 18 Years of Age) With Inadequately Controlled Partial-onset Seizures
Brief Summary: This study is designed to investigate the short- and long-term effects of perampanel on cognition, growth, and development in adolescents.


Options:
A: Arm Label: Perampanel; Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: perampanel | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: perampanel; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Perampenal (Core Study); Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo (Core Study); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Perampanel (Extension Phase); Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel (Extension Phase), Perampenal (Core Study) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Core Study)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Nonsmoking
Brief Summary: The research is based on a chronic disorder model of cigarette smoking which suggests that long-term treatment targeted to prevent relapse may be useful. Based on this model, the investigators have developed a relapse prevention treatment to intervene on five areas important in relapse prevention, including fluctuating motivation, depression, withdrawal, weight gain, and social support. This treatment protocol has produced high long-term abstinence rates when implemented in a clinical research setting. The current study will evaluate the treatment model when implemented in a medical outpatient setting.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
B: Arm Label: Extended Brief Contact; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Check-ins with medical staff | Arm Label: Extended Health Education; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Health Model | Arm Label: Extended Relapse Prevention plus varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Arm Label: Extended Relapse Prevention; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Initial Individual counseling; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Check-ins with medical staff; Assigned to Arm(s): Extended Brief Contact | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Health Model; Assigned to Arm(s): Extended Health Education | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Relapse Prevention Model; Assigned to Arm(s): Extended Relapse Prevention, Extended Relapse Prevention plus varenicline
C: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Nonsmoking
Brief Summary: The research is based on a chronic disorder model of cigarette smoking which suggests that long-term treatment targeted to prevent relapse may be useful. Based on this model, the investigators have developed a relapse prevention treatment to intervene on five areas important in relapse prevention, including fluctuating motivation, depression, withdrawal, weight gain, and social support. This treatment protocol has produced high long-term abstinence rates when implemented in a clinical research setting. The current study will evaluate the treatment model when implemented in a medical outpatient setting.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Extended Brief Contact; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Check-ins with medical staff | Arm Label: Extended Health Education; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Health Model | Arm Label: Extended Relapse Prevention plus varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Arm Label: Extended Relapse Prevention; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Initial Individual counseling; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Check-ins with medical staff; Assigned to Arm(s): Extended Brief Contact | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Health Model; Assigned to Arm(s): Extended Health Education | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Relapse Prevention Model; Assigned to Arm(s): Extended Relapse Prevention, Extended Relapse Prevention plus varenicline
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study
Brief Summary: The purpose of this study is to investigate the efficacy and safety of eslicarbazepine acetate (BIA 2-093) as monotherapy for patients with newly diagnosed partial-onset seizures.


Options:
A: Arm Label: Healthy control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Carbamazepine group; Type: EXPERIMENTAL; Interventions: Drug: Carbamazepine | Arm Label: Oxcarbazepine group; Type: EXPERIMENTAL; Interventions: Drug: Oxcarbazepine | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine group | Intervention Type: DRUG; Name: Oxcarbazepine; Assigned to Arm(s): Oxcarbazepine group
B: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
C: Arm Label: Carbamazepine controlled release; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eslicarbazepine acetate (BIA 2-093) | Arm Label: Eslicarbazepine acetate; Type: EXPERIMENTAL; Interventions: Drug: Eslicarbazepine acetate (BIA 2-093) | Intervention Type: DRUG; Name: Eslicarbazepine acetate (BIA 2-093); Assigned to Arm(s): Carbamazepine controlled release, Eslicarbazepine acetate
D: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Arm Label: Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Lamotrigine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oklahoma Weight Concerns Quitline: a Randomized Cessation Trial
Brief Summary: The purpose of the "Weigh2Quit" study was to test in a randomized trial, a "weight concerns" intervention designed to reduce weight concerns that might impact cessation, increase physical activity and adherence to tobacco treatment, increase confidence in quitting, improve tobacco quit rates and decrease weight gain post-quit.


Options:
A: Arm Label: Intervetion; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Concerns | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Weight Concerns; Assigned to Arm(s): Intervetion
B: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean diet counseling | Arm Label: CONTROL GROUP: WITHOUT CHANGES IN DIET; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mediterranean diet counseling; Assigned to Arm(s): INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING
D: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of three different doses of A-623 administered in addition to standard therapy in subjects with active SLE disease


Options:
A: Arm Label: A-623 high dose weekly; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: A-623 low dose weekly; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: A-623 high dose every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comparator | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 high dose weekly | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 low dose weekly | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 high dose every 4 weeks | Intervention Type: OTHER; Name: Placebo Comparator; Assigned to Arm(s): Placebo
B: Arm Label: Part A, 1 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 1 mg/kg CNTO 136 | Arm Label: Part A, 4 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 4 mg/kg CNTO 136 | Arm Label: Part A, 10 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 10 mg/kg CNTO 136 | Arm Label: Part B, 10 mg/kg CNTO 136/placebo; Type: EXPERIMENTAL; Interventions: Drug: 10 mg/kg CNTO 136, Drug: Placebo | Intervention Type: DRUG; Name: 1 mg/kg CNTO 136; Assigned to Arm(s): Part A, 1 mg/kg CNTO 136 | Intervention Type: DRUG; Name: 4 mg/kg CNTO 136; Assigned to Arm(s): Part A, 4 mg/kg CNTO 136 | Intervention Type: DRUG; Name: 10 mg/kg CNTO 136; Assigned to Arm(s): Part A, 10 mg/kg CNTO 136, Part B, 10 mg/kg CNTO 136/placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part B, 10 mg/kg CNTO 136/placebo
C: Arm Label: HCQ; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydroxychloroquine (Z0188) | Arm Label: Placebo; Type: OTHER; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydroxychloroquine (Z0188); Assigned to Arm(s): HCQ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI 545 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MEDI 545; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 4 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 5

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Blood Pressure Monitoring Program
Brief Summary: The goal of this project is to improve hypertension control at Kaiser Permanente Colorado (KPCO) by implementing a population-based multi-factorial intervention that uses home BP monitors that can download BP readings to KPCO's health records via internet, interactive voice response (IVR) technology, and multidisciplinary care team. Participants will be randomized to either the home blood pressure monitoring group receiving the multi-factorial intervention or the usual care group who will be receiving Kaiser standard of care. We will determine the proportion of patients in each group who achieve their target BP goals at 6 months, according to national clinical practice guidelines. The study hypothesis is that a higher proportion of patients with uncontrolled hypertension in the home blood pressure monitoring (HBPM) group will achieve their target blood pressure compared to those in the usual care (UC) group.


Options:
A: Arm Label: 24 Month PPCM BP; Type: EXPERIMENTAL; Interventions: Other: 24 Month PPCM BP | Arm Label: 9 Month PPCM BP; Type: EXPERIMENTAL; Interventions: Other: 9 Month PPCM BP | Arm Label: PPCM Asthma; Type: SHAM_COMPARATOR; Interventions: Other: PPCM Asthma | Arm Label: BP Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PPCM Asthma; Assigned to Arm(s): PPCM Asthma | Intervention Type: OTHER; Name: 24 Month PPCM BP; Assigned to Arm(s): 24 Month PPCM BP | Intervention Type: OTHER; Name: 9 Month PPCM BP; Assigned to Arm(s): 9 Month PPCM BP
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Blood Pressure Monitoring Group; Type: EXPERIMENTAL; Interventions: Behavioral: Home Blood Pressure Monitoring | Intervention Type: BEHAVIORAL; Name: Home Blood Pressure Monitoring; Assigned to Arm(s): Home Blood Pressure Monitoring Group
C: Arm Label: ISTOP-ADE; Type: EXPERIMENTAL; Interventions: Other: ISTOP-ADE | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ISTOP-ADE; Assigned to Arm(s): ISTOP-ADE
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home Blood Pressure Monitoring Program
Brief Summary: The goal of this project is to improve hypertension control at Kaiser Permanente Colorado (KPCO) by implementing a population-based multi-factorial intervention that uses home BP monitors that can download BP readings to KPCO's health records via internet, interactive voice response (IVR) technology, and multidisciplinary care team. Participants will be randomized to either the home blood pressure monitoring group receiving the multi-factorial intervention or the usual care group who will be receiving Kaiser standard of care. We will determine the proportion of patients in each group who achieve their target BP goals at 6 months, according to national clinical practice guidelines. The study hypothesis is that a higher proportion of patients with uncontrolled hypertension in the home blood pressure monitoring (HBPM) group will achieve their target blood pressure compared to those in the usual care (UC) group.


Options:
A: Arm Label: CarePartners+; Type: EXPERIMENTAL; Interventions: Behavioral: Caregiver website | Arm Label: CarePartners-; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Caregiver website; Assigned to Arm(s): CarePartners+
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Blood Pressure Monitoring Group; Type: EXPERIMENTAL; Interventions: Behavioral: Home Blood Pressure Monitoring | Intervention Type: BEHAVIORAL; Name: Home Blood Pressure Monitoring; Assigned to Arm(s): Home Blood Pressure Monitoring Group
C: Arm Label: 1 concurrent smoking cessation; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral counseling plus contingency management | Arm Label: 2 deferred smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral counseling plus contingency management | Intervention Type: BEHAVIORAL; Name: behavioral counseling plus contingency management; Assigned to Arm(s): 1 concurrent smoking cessation, 2 deferred smoking cessation
D: Intervention Type: DEVICE; Name: Electronic Medical Record (EMR) to clinician's in-basket; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Automated Voice Message (AVM) reminder to patient's phone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Pharmacy Team phone call-letter followup; Assigned to Arm(s): N/A

Answer: B